Skip to main content
. 2024 Nov 30;15:10438. doi: 10.1038/s41467-024-54762-5

Fig. 6. TRIM7 mediates its antiviral effects by inhibiting caspase-6 activation.

Fig. 6

a Viral titers of HEK293T-hACE-2 cells overexpressing TRIM7 WT and infected with SARS-CoV-2 WT or M-K14/15R at MOI 0.1 and treated with vehicle (DMSO) or 50 μM of Z-VEID-FMK 24 h post infection. Two-way ANOVA Tukey’s multiple comparisons (****p < 0.0001). b Western blot analysis of A549 WT and TRIM7 KO cells transfected with SARS-CoV-2 N protein or empty vector and treated with Staurosporine (STS) *indicates a cleaved form of N (blot is representative of two independent experiments). c Weight loss of WT female mice infected intranasally with SARS-CoV-2 WT, treated intraperitoneally with caspase-6 inhibitor or vehicle. Mock (n = 6 each) vehicle (n = 5) or Z-VEID-FMK (n = 6). Two-way ANOVA Tukey’s multiple comparisons (*p = 0.03) (d) weight loss Trim7−/− female mice infected as in (c), vehicle mocks (n = 5 each) infected vehicle (n = 4) or Z-VEID-FMK (n = 6). e Viral titers in lung (WT n = 5 and 6, Trim7−/− n = 5 and 4, respectively). One-way ANOVA Tukey’s multiple comparisons (**p = 0.002, p = 0.003, *p = 0.02). f IFN-β mRNA multiple T-test comparison (***p = 0.0003, **p = 0.001). g ISG54 mRNA expression levels in the lung. One-way ANOVA Tukey’s multiple comparisons (*p = 0.03, p = 0.01, ***p = 0.0002, ****p < 0.0001). h Scheme of the multiple functions of TRIM7 during SARS-CoV-2 infection. Data were depicted as mean ± SEM. DPI days post infection, CoV-2 SARS-CoV-2. Source data are provided in the Source data file.